PROTÉGEN Randomised Controlled Trial published at International Congress

PROTÉGEN first randomised controlled clinical trial (RCT) was recently presented by Hospital Tuanku Jaafar, Seremban nephrology team at ISN World Congress of Nephrology, 12th-15th April, Melbourne, Australia.

The study shows that PROTÉGEN (collagen protein peptides) is beneficial to peritoneal dialysis patients. It increased protein intake, improved anthropometry measurements and lowered serum phosphate level.

PROTÉGEN is the only collagen protein peptides in the market tested clinically in public hospital settings with proven display of safety and efficacy.